At TCR2 Therapeutics we have a bold vision – to cure cancer by using our immune system in a more natural way. We have pioneered a novel class of T cell therapies that utilize the full signaling power of complete T cell receptors (TCR). Our unique proprietary TRuC™ platform reprograms the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. We have demonstrated superior activity against both hematological and solid tumor targets in preclinical models compared to CAR-T and believe our TRuC™-reprogrammed T cells will serve as a backbone for novel solid tumor therapies.
The company was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. We have since assembled a world class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA.